A recent study found that tirzepatide, the active ingredient in Zepbound and Mounjaro, could reduce the risk of hospitalization and death from heart failure. The GLP-1 drug is approved to treat ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart ...

Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday.

Tirzepatide lowered risk of worsening heart failure and CVD death for obese adults American Heart Association Scientific Sessions 2024, Abstract 4171195 Reports and Proceedings American Heart ...

Treatment with tirzepatide reduced the risk of time-to-first occurrence of heart failure outcomes by 38% compared with placebo.

Tirzepatide reduced the risk of heart failure outcomes – heart failure urgent visit or hospitalization, oral diuretic intensification, or cardiovascular death by 38% compared to placebo.

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

Tirzepatide, the active ingredient in these diabetes and weight loss drugs, slashed the likelihood of hospitalization and death in a new study.

Tirzepatide showed a 38% reduction in the risk of heart failure outcomes, assessed as a composite endpoint, compared to placebo. Risk of hospitalization for heart failure was reduced by 56%.

Tirzepatide showed a 38% reduction in the risk of heart failure outcomes, assessed as a composite endpoint, compared to placebo. Risk of hospitalization for heart failure was reduced by 56%.

Data from the SUMMIT clinical trial demonstrated that tirzepatide lowered the risk of negative heart failure outcomes and enhanced symptoms and physical limitations when tested with three different ...

(NewMediaWire) - November 16, 2024 - CHICAGO In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a ...